The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin.

[1]  H. Birgisson,et al.  Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC , 2019, Annals of Surgical Oncology.

[2]  J. Tuynman,et al.  RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score , 2019, Annals of Surgical Oncology.

[3]  M. Pocard,et al.  A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7. , 2019, European Journal of Surgical Oncology.

[4]  S. Roka,et al.  Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin , 2018, Annals of surgery.

[5]  V. Giner-Bosch,et al.  Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis , 2018, Clinical and Translational Oncology.

[6]  R. Yaeger,et al.  Colorectal cancer genomics and designing rational trials. , 2018, Annals of translational medicine.

[7]  I. B. Borel Rinkes,et al.  Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases , 2018, The British journal of surgery.

[8]  M. Zucchetti,et al.  High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation , 2017, Pharmaceutical Research.

[9]  F. Pedeutour,et al.  Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. , 2017, American journal of surgery.

[10]  H. Sakamoto,et al.  Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. , 2017, Anticancer research.

[11]  C. Karapetis,et al.  Colorectal cancer: Metastases to a single organ. , 2015, World journal of gastroenterology.

[12]  M. Heskel,et al.  Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. , 2015, Surgical oncology.

[13]  F. Pontén,et al.  High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort , 2015, PloS one.

[14]  M. Delorenzi,et al.  Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. , 2015 .

[15]  Miho Kakuta,et al.  Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer , 2014, Journal of surgical oncology.

[16]  Jeffrey S. Morris,et al.  Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. , 2013, The oncologist.

[17]  S. Hiotis,et al.  Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. , 2013, Surgical oncology.

[18]  N. Petrelli,et al.  Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States , 2013, Annals of Surgical Oncology.

[19]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Yatabe,et al.  BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer , 2011, British Journal of Cancer.

[22]  A. Stojadinovic,et al.  KRAS Status in Patients With Colorectal Cancer Peritoneal Carcinomatosis and Its Impact on Outcome , 2010, American journal of clinical oncology.

[23]  H. Lippert,et al.  Primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[25]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[26]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Tinteren,et al.  Recurrences after Peritoneal Carcinomatosis of Colorectal Origin Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome , 2004, Annals of Surgical Oncology.

[29]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[31]  P. Sugarbaker,et al.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.